NewKerala.com

Semaglutide Patent Expiry to Unlock Over ₹50,000 Crore for Generic Drugmakers

The patent expiry of semaglutide, a key GLP-1 drug, is projected to create a massive opportunity exceeding ₹50,000 crore for generic manufacturers over the next 12-15 months. The revenue will be split among 10-15 players across India, regulated markets like Canada and Brazil, and emerging markets, with prices expected to drop 30-50% initially and up to 75% over time. In India, the generic launch in Q1 FY27 could boost overall market growth by 0.5-1%, accelerating therapy adoption. Leading Indian pharma companies like Alkem, Dr. Reddy's, and Sun Pharma are already positioned with approvals, while success hinges on regulatory timelines and competitive dynamics in each market.

Key Points: Generic Semaglutide Patent Expiry Opens ₹50,000 Cr Opportunity

  • ₹50,000+ Cr Revenue Opportunity
  • 30-75% Price Cuts Expected
  • 10-15 Generic Players to Compete
  • IPM Growth Boost of 0.5-1%
2 min read

Generic Semaglutide patent expiry opens over Rs 50,000 Crore opportunity for drugmakers: Report

Patent expiry of semaglutide drugs is set to unlock a ₹50,000+ crore revenue opportunity for generic manufacturers in India and key global markets over the next 12-15 months.

"The impending patent expiry... is expected to unlock a revenue opportunity exceeding Rs 50 billion - Systematix Institutional Research"

New Delhi, January 3

The impending patent expiry of semaglutide drugs across India, emerging markets and select regulated markets such as Canada and Brazil is expected to unlock a revenue opportunity exceeding Rs 50 billion for generic drug manufacturers over the next 12-15 months, according to an industry update by Systematix Institutional Research.

The opportunity is likely to be shared among 10-15 Indian and global generic players. For FY27, incremental revenues are estimated at Rs 10-20 billion from India's branded formulations market, around Rs 45 billion from regulated markets like Canada and Brazil, and Rs 5-10 billion from emerging markets.

While regulated markets could see a sharp near-term upside, the opportunity there may moderate over time due to pricing pressure and competition, the report noted.

In India, the launch of generic semaglutide, expected in the first quarter of FY27, is projected to boost overall Indian Pharmaceutical Market (IPM) growth by 0.5-1%.

Prices are anticipated to be 30-50% lower than current levels initially, with the potential for deeper cuts of up to 70-75% over time. This is expected to significantly accelerate adoption of GLP-1 therapies among diabetics.

Market leadership within the GLP-1 segment is likely to remain concentrated among 5-10 players. At present, Alkem Laboratories, Dr. Reddy's Laboratories and Sun Pharma have secured regulatory approvals in India, while other players await clearance, the report noted.

Zydus Lifesciences is pursuing a differentiated injectable version, which could offer a competitive edge despite its relatively smaller diabetes franchise, it said.

In regulated markets, the combined semaglutide market in Canada and Brazil is estimated at nearly USD 2 billion annually. Assuming a 50% price erosion post-generic entry and 50% market share capture by generics, the addressable opportunity could be around USD 500 million.

However, analysts cautioned that success will depend heavily on timely regulatory approvals and competitive dynamics. Dr. Reddy's could emerge as the first Indian generic entrant in Canada, while Sun Pharma may enjoy a first-mover advantage in Brazil.

Emerging markets are expected to offer steadier, longer-term growth with comparatively lower regulatory risk. Companies such as Sun Pharma, Dr. Reddy's, Alkem, Biocon and OneSource Specialty Pharma are seen as better positioned to capitalise, aided by existing diabetes portfolios and partnerships.

Ancillary beneficiaries are also expected, including Shaily Engineering Plastics, a key global supplier of pen devices used in injectable therapies, which could see meaningful demand growth as generic launches scale up.

- ANI

Share this article:

Reader Comments

S
Sarah B
As someone who follows the pharma sector closely, this report highlights a massive opportunity. The focus on Canada and Brazil as regulated market entry points is smart. However, the caution about pricing pressure is real – the race to the bottom on price can hurt margins. Execution and supply chain will be key.
V
Vikram M
Interesting to see Zydus working on a differentiated injectable. In a crowded generic market, that kind of innovation is what can create a lasting brand. Hope other Indian companies also focus on value-added versions, not just being the cheapest. Jai Hind!
P
Priya S
While the economic opportunity is huge, I hope the quality and efficacy of these generic versions are given top priority. The Indian pharma industry's reputation is at stake. Regulatory bodies must ensure strict oversight. Patient safety cannot be compromised for profit.
R
Rohit P
Boosting IPM growth by 0.5-1% might sound small, but in a market this size, it's significant. This is exactly how our pharmaceutical sector becomes a global powerhouse – by making critical medicines affordable and accessible. Sun Pharma and Dr. Reddy's leading the charge! 💪
M
Michael C
The ripple effect mentioned is fascinating. Companies like Shaily Engineering supplying pen devices will benefit too. It shows how a single drug's patent expiry can stimulate an entire ecosystem. Smart investors should look at the ancillary players as well.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50